http://cafepharma.com/boards/threads/repatha-outcomes-to-be-delayed-further.598985/#post-5728142
From the Amgen board on Repatha outcomes:
"Now I am hearing that the outcomes are not expected to be publicly known until second semester of next year. Inside source got preliminary data that isn't telling a story we were hoping for. Not completely over, but it will take some analytical prowess to scrub the data and tell us specific patient types and levels that can possibly benefit. There is potentially some bad news for patients with too low of cholesterol level. Also, it doesn't appear to follow a consistent trajectory once the ldl levels drop below 70. Once this level is reached there is less benefit per ldl point dropped, and the lower it drops the less benefit there seems to be. A law of diminishing returns appears to rear its ugly head. Potentially bigger benefit in patients on lower statin dose and higher baselines. May not show to be great for everyone but I am hoping we find specific patient types to target. Fingers crossed!"
From the Amgen board on Repatha outcomes:
"Now I am hearing that the outcomes are not expected to be publicly known until second semester of next year. Inside source got preliminary data that isn't telling a story we were hoping for. Not completely over, but it will take some analytical prowess to scrub the data and tell us specific patient types and levels that can possibly benefit. There is potentially some bad news for patients with too low of cholesterol level. Also, it doesn't appear to follow a consistent trajectory once the ldl levels drop below 70. Once this level is reached there is less benefit per ldl point dropped, and the lower it drops the less benefit there seems to be. A law of diminishing returns appears to rear its ugly head. Potentially bigger benefit in patients on lower statin dose and higher baselines. May not show to be great for everyone but I am hoping we find specific patient types to target. Fingers crossed!"